Oxurion NV — Major Shareholding Notification 2025

Jul 15, 2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – July 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on July 15, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 14, 2025, it held 2,751,917 shares of the then outstanding 12,428,021 shares, and therefore crossed under the threshold (25%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

^1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
	Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entitles)
	Atlas Special Opportunities II LLC			2500 Westchester Avenue, Sulte 401, Purchase, NY 10577
	6) Persons that dispose of votinq rights (only to be filled in it art. 7 of the Law applies)
	Name			Address (for legal entitles)
	Please continue entering the information in part it concerning the
B	persons referred to In Sections 5 and 6			Part II
7) Date on which the threshold is crossed
			14/07/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		25
	If the holding has fallen below the lowest threehold, you have the option of not entering any numbers in Section 10
9) Denominator
		12,428,021
Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification		After the fransaction
	# of voting rights			# of voting rights		% of voting rights
Holders of voting rights			Linked to securities	Not linked to the SPOUTHER	Linked to securities	Not linked to the POLITIES

B) Equivalent financial Instruments	After the transaction
Holders of equivalent financial instruments	Type of financial Instrument	Expiration date	Exercise perfod or date	# of voting rights that may be acquired if the Instrument is exercised	% of voting rights	Settlement
							+
TOTAL			0	0.00%
t The zotals will be updated once you have clicked on «CALCULATE>

TOTAL (A & B)		# of voting rights % of voting rights
	CALCULATE	2,751,917	22.14%

11) Full chain of controlled undertakings through which the holding is effectively held, it applicable

	Atlas Special Opportunities II LLC is not a controlled entity.
12) In case of proxy voting for only one GM
Holder		will cease to hold / will hold again	voting rights as of	(DD/MM/YYYY)
13) Additional information
denominator = 12,428,021). denominator = 12,428,021).	On 04 July 2025 with setternet date on 03 July 2025, Atias Special Club 25, 265 Stares in Diulton N, as a reall of Mr.is is a reality in shares in 3,34,534 shares in 2,335, On 10 uly 2025 with setterners date on 14 July 2025, Ata-Special Charles II LC sold 35, 564 stares in Diurion N, as a reall of which is stareholding decreased of, 75, 97 shar

	Done at New York
On		15/07/2025 (DD/MM/YYYY)
	Name & capacity Patrick Vance, Proxyholder		Patrick Vance Signature

For security reasons, the unsigned form in xisx format should
be transmitted to trp.fin@trma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in EDE format should also be
transmitted.